Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2007-10-30
2010-11-16
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C536S023100
Reexamination Certificate
active
07833786
ABSTRACT:
The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
REFERENCES:
patent: 5326859 (1994-07-01), Sugano et al.
patent: 5468609 (1995-11-01), Revel et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5554513 (1996-09-01), Revel et al.
patent: 5559012 (1996-09-01), Brailly et al.
patent: 5591827 (1997-01-01), Brakenhoff et al.
patent: 5618700 (1997-04-01), Novick et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5639455 (1997-06-01), Shimanura et al.
patent: 5723120 (1998-03-01), Brakenhoff et al.
patent: 5789552 (1998-08-01), Savino et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5849283 (1998-12-01), Ciliberto
patent: 5854398 (1998-12-01), Chang et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 5888511 (1999-03-01), Shurkovich et al.
patent: 5914106 (1999-06-01), Ciliberto
patent: 5942220 (1999-08-01), Warren et al.
patent: 5958400 (1999-09-01), Ruben et al.
patent: 5972902 (1999-10-01), Ciliberto
patent: 6010864 (2000-01-01), Hoeprich et al.
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6121423 (2000-09-01), Tsuchiya et al.
patent: 6261560 (2001-07-01), Tsujinake et al.
patent: 2002/0010320 (2002-01-01), Fett
patent: 2003/0113342 (2003-06-01), Zhao et al.
patent: 800829 (1997-10-01), None
patent: WO 91/08774 (1991-06-01), None
patent: WO 94/09138 (1994-04-01), None
patent: WO 01/58956 (2001-08-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading Fv Structure and Diversity in Three Dimensions.
Casset et al, Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Coleman P. M., Research in Immunology, 145:33-36, 1994.
MacCallum et al, J. Mol. Biol., 262, 732-745, 1996.
Brakenhoff, et al., “Structure-Function Analysis of Human IL-6 Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino-and Carboxyl-Terminal Deletion Mutants,” The Journal of Immunology, 145(2):561-568 (1990).
Brakenhoff, et al., “Molecular Cloning and Expression of Hybridoma Growth Factor inEscherichia coli,” The Journal of Immunology, 139(12): 4116-4121 (1987).
Van Zaanen, et al., Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp130, Leukemia & Lymphoma, 31(31(5-6)): 551-558 (1998).
Van Zaanen, et al., Endogenous Interleukin 6 Production in Multiple Myeloma Patients Treated with Chimeric Monoclonal Anti-IL6 Antibodies Indicates the Existence of a Positive Feed-back Loop, Journal of Clinical Investigations, The American Society for Clinical Investigation, Inc., 98(6): 1441-1448 (1996).
Van Oers, Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study, British Journal of Haematology, 102: 783-790 (1998).
Baselga, et al., “Receptor Blockage with Monoclonal Antibodies as Anti-Cancer Therapy,” Pharmaceutical Therapy, 64: 127-154 (19940.
Matsuda, et al., “Establishment of an interleukin 6 (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies,” European Journal of Immunology, 18: 951-956 (1988).
Seideman, et al., “A novel monoclonal antibody screening method using the Luminex-100 microsphere system,” Journal of Immunology Methods, 267: 165-171 (2002).
Bataille, et al., Biologica Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma, Blood, 86(2): 685-691 (1995).
Eliceiri, et al., The Role of Alpha V Integrins During Angiogenesis: Insights into Potential Mechanisms of Action and Clinical Development, Journal of Clinical Investigations, 103(9): 1227-1230 (1999).
Trikha, et al., “Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence,” Clinical Cancer Res., 9: 4653-4665 (2003).
Orlandi, et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proceedings of the National Academy of Science USA 86: 3833-3837 (1989).
Brakenhoff, et al., “Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino-and Carboxyl-Terminal Deletion Mutants,” Journal of Immunology, 145: 561-568 (1990).
Sato, et al., “Humanization of an Anti-Human IL-Mouse Monoclonal Antibody Glycosylated in its Heavy Chain Variable Region,” Human Antibodies and Hybridomas, 7(4): 175-183 (1996).
Naka, et al., “The Paradigm of IL-6: From Basic Science to Medicine,” Arthritis Research, Current Science, 4(3): S233-S242 (2002).
Petrov, et al., “Immunology,” Medicine Publishers, 56-58 (1987), Russian Article and English translation.
EP Supplementary Search Report dated Jul. 24, 2006 for EP Application No. 02784436.4.
Paul, “Fv Struture and Diversity in Three Dimentions,” Fundamental Immunology, 3rdedition pp. 292-295 (1993).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Science, USA 79: 1979 (1982).
Cruse and Lewis, Illustrated Dictionary of Immunology, p. 19 (1995).
CL First Substantive Report for Application No. 2610-2002 dated Jun. 4, 2007.
Giles-Komar Jill
Knight David
Peritt David
Trikha Mohit
Centocor, Inc.
Dow Kenneth J.
Halvorson Mark
Yu Misook
LandOfFree
Anti-IL-6 antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-6 antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-6 antibodies, compositions, methods and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159656